Explore published research on cardiovascular, including study methods and limitations.
Extended daily THC use reversed typical heart rate increases, instead slowing heart rate and lowering blood pressure through apparent sympathetic nervous system suppression.
Marijuana and amphetamine produced additive cardiovascular effects but psychomotor impairment came only from marijuana, with no stimulant counteraction.
Combining cannabis with dextroamphetamine produced impairment similar to cannabis alone. The stimulant did not counteract cannabis-related motor deficits.
Four youths injected boiled cannabis-seed tea intravenously. All developed shock, organ damage, and bleeding. All survived but the reactions were potentially fatal.
A 1978 medical review identified cannabis as promising for glaucoma and asthma but flagged cardiovascular risks during exercise and preliminary concerns about lung and immune effects.
A major 1986 pharmacological review found cannabis's greatest health concern was its impact on youth development, while finding no proven brain damage and limited physical dependence in adults.
Review finding cannabis increases heart rate with rapid tolerance development, poses minimal risk for young healthy users but significant risks for people with existing cardiovascular disease.
Review comparing cardiovascular effects of five substance classes, finding cannabis posed fewer heart risks than opiates, amphetamines, or alcohol, though cognitive effects were noted.
Comprehensive review finding endocannabinoids play protective roles during cardiovascular emergencies like shock and heart attack, acting through CB1, vanilloid, and possibly novel receptors.
Four large trials of CB1 blocker rimonabant showed significant weight loss, improved lipids and blood sugar, and increased smoking quit rates. Later withdrawn due to psychiatric side effects.
Review of case reports found evidence linking marijuana to heart rhythm problems, heart attacks, and vascular complications, with increasing concern for aging long-term users.
CBD reduced heart attack damage by 66% in rats and dramatically lowered inflammation markers, but the effect required a living system and didn't work in isolated hearts.
Case report of a young man who had a heart attack with acute coronary thrombosis shortly after smoking marijuana, treated successfully with emergency angioplasty.
Review found limited evidence that cannabis use may worsen metabolic health in psychosis patients already at elevated cardiovascular risk, though long-term effects remain unclear.
Review found CB1 receptor antagonists show metabolic benefits for obesity but psychiatric side effects limit use, proposing "neutral antagonists" as a safer next-generation approach.
A chronic cannabis user experienced a heart attack with slow coronary flow but no arterial blockages, adding to case reports linking cannabis to acute cardiac events in people without typical risk factors.
CBD reduced cardiac dysfunction, inflammation, fibrosis, oxidative stress, and cell death in diabetic mice and human heart cells exposed to high glucose.
Comprehensive review found recreational cannabis adverse effects were generally minor, with overall harms appearing less serious than alcohol, though vulnerable individuals faced greater risks.
Inpatient study found blood pressure increases up to 22.8 mmHg systolic when daily cannabis users stopped, with a subset showing potentially dangerous elevations.
A 24-year-old soccer player with heavy cannabis use and no other risk factors had a heart attack during exercise due to a blocked coronary artery.
Chronic cannabis smokers had 50% more visceral belly fat, lower HDL, and fat cell insulin resistance, but normal blood sugar, liver fat, and pancreatic function.
Three patients experienced cardiac arrest after cannabis use through different mechanisms, including one young person without cardiovascular risk factors.
A 21-year-old regular cannabis user had a heart attack with normal arteries, confirmed by intravascular ultrasound, suggesting cannabis can trigger clotting without underlying arterial disease.
French national data identified 35 serious cardiovascular events in cannabis users (2006-2010), including 20 heart attacks and 9 deaths, mostly in young men.
Case report of a 32-year-old woman who developed takotsubo (stress) cardiomyopathy during an episode of cannabinoid hyperemesis syndrome after resuming marijuana use.
Review for cardiologists documents temporal associations between marijuana use and heart attacks, sudden cardiac death, stroke, and arterial disease, urging awareness as legalization expands.
Case of a 38-year-old man who developed cannabinoid hyperemesis syndrome from K2 synthetic cannabis, diagnosed after extensive negative workup, with symptoms relieved only by hot showers.
Case report of CHS presenting as cyclical vomiting relieved by hot baths in a chronic cannabis user, emphasizing the need for emergency department recognition.
A pregnant woman with multiple admissions for severe vomiting and esophageal tears was eventually diagnosed with CHS after compulsive bathing behavior was noted.
Case report of CHS in pregnancy mistaken for hyperemesis gravidarum, reinforcing the need for marijuana history in pregnant patients with severe, unexplained vomiting.
Controlled study of 16 adults found combining THC with methylphenidate produced additive heart rate increases and unique subjective effects, while THC impaired attention that MPH partially offset.
Case report of cannabinoid hyperemesis syndrome with atypical features including bradycardia and cold-water relief instead of the classic hot-water relief pattern.
Chronic FAAH inhibition in hypertensive rats further elevated liver endocannabinoid levels but worsened oxidative stress, despite reducing inflammation.
Natural variation in anandamide levels and FAAH activity in a specific brainstem region correlated with resting heart rate in rats, with anandamide injection increasing heart rate.
Just one minute of marijuana secondhand smoke impaired blood vessel function for 90+ minutes, longer than tobacco smoke, and the effect was caused by combustion products, not cannabinoids.
Young men with heart attacks who tested positive for cannabis had more severe presentations and worse coronary findings than drug-free patients, despite fewer traditional risk factors.
Review placing marijuana cardiac risk in context: scattered reports of sudden death exist, but the incidence is rare compared to cocaine and amphetamines.
Conservative treatment improved critical leg ischemia in 23 patients with arteritis (8 cannabis-associated), but only 13% achieved smoking cessation.
Systematic review of 15 studies finding THC does not improve aerobic performance or strength, inhibits exercise-induced asthma, and triggered angina at lower workloads in all cardiac-vulnerable subjects.
Review explaining that synthetic cannabinoids are full agonists with higher binding affinity than THC (a partial agonist), producing more intense effects and more severe neurological and cardiovascular complications.
Overview of the endocannabinoid system's roles across physiological processes including emerging cardioprotective potential, noting that psychoactive side effects and incomplete mechanistic understanding limit therapeutic development.
Case report of a chronic cannabis user who developed both cannabinoid hyperemesis syndrome and coronary vasospasm causing a heart attack, suggesting cardiac evaluation in CHS patients with chest pain.
Hypothesis paper proposing that CHS results from chronic cannabis disruption of the HPA stress axis and sympathetic nervous system, causing endocannabinoid dysfunction and loss of autonomic balance.
Rat study found synthetic cannabinoids lower temperature through CB1 receptors but raise blood pressure through a separate sympathetic nervous system mechanism unrelated to cannabinoid receptors.
Case series of 8 patients with marijuana-associated heart attacks, average age 40, with half having minimal or no traditional cardiovascular risk factors.
Review of 98 reported cases found cannabinoid-related strokes mainly affected young male chronic users, with reversible vasoconstriction as a proposed mechanism in 27% of cases.
Review finds synthetic cannabinoids bind brain receptors with much higher potency than natural cannabis, causing psychosis, kidney failure, cardiac problems, and death.
Analysis of 2.3 million hospitalizations found mood disorders topped psychiatric diagnoses (20.6%) among marijuana users, with increasing cardiovascular events and AMI as a top mortality predictor (OR 4.59).
Study of 1,669 ED patients found cocaine and cannabis use, both individually and combined, associated with significantly higher 36-month mortality risk after demographic adjustment.
Case report of a patient who developed ECG changes mimicking critical coronary blockage after smoking PCP-laced cannabis. Coronary angiography was normal.
National database analysis found cannabis use independently predicted heart failure and stroke risk in adults 18-55, even after adjusting for tobacco, alcohol, and traditional cardiovascular risk factors.
A young woman had an acute heart attack (anterior STEMI) shortly after using synthetic cannabis, highlighting the serious cardiovascular risks of these potent compounds.
National database analysis found heart attack admissions among cannabis users rose 32% from 2010-2014, with in-hospital mortality up 60%, predominantly in males averaging age 41.
First-episode schizophrenia patients who used cannabis gained significantly less weight during 12 months of antipsychotic treatment, with less metabolic deterioration than non-users.
A review of synthetic cannabinoid toxicities documented severe effects across multiple organ systems including cardiac arrest, psychosis, seizures, and kidney failure, plus deaths from contaminated products.
A case of cardiac tamponade in a synthetic cannabinoid user adds to the evidence of serious cardiovascular toxicity from these substances, which can cause a wide range of heart complications.
Six synthetic cannabinoid users developed multiple organ failure including severe muscle breakdown, kidney failure, and the first reported case of SC-associated liver failure requiring transplantation.
A 25-year-old developed delayed brain hemorrhage days after synthetic cannabinoid use, despite an initially normal brain CT, highlighting the risk of late intracranial complications.
A 16-patient cohort with bleeding from rat poison-contaminated synthetic cannabinoids showed 75% had severely abnormal clotting, one died, and treatment averaged $5,300 per hospitalization.
A synthetic marijuana user developed severe blood clotting failure and cardiac arrest from brodifacoum (rat poison) contamination, adding to evidence of a contamination crisis.
A balanced review found cannabis is associated with multiple health harms but causal evidence is largely missing, while cannabinoid-based drugs show legitimate therapeutic potential across many conditions.
Review identifying at least 13 deaths and 35 serious cardiovascular emergencies linked to cannabis use, plus multiple strokes and vascular arteritis cases, likely underestimating the true incidence.
Rat study shows boosting endocannabinoids in the hippocampus prevented both the immediate cardiovascular stress response and delayed anxiety 24 hours later, both through CB1 receptor signaling.
Case report of a 26-year-old male who had a heart attack and heart failure after a cannabis smoking binge, adding to rare but concerning documented cardiovascular events in young cannabis users.
Mouse study shows CB1 antagonists and CB2 agonists protect against clozapine-induced heart damage, with opposite cannabinoid receptor roles in cardiotoxicity.
Review finds cannabis smoking produces similar combustion chemicals and cardiovascular risks as tobacco, including heart attacks, arrhythmias, and strokes, potentially at younger ages.
Colorado study found edible cannabis accounted for 0.32% of THC sales but 10.7% of cannabis ER visits, with higher rates of psychiatric, intoxication, and cardiovascular events.
Study of 4,028 adults with congenital heart disease across 15 countries found cannabis-only use had negligible impact, while cannabis-tobacco co-use moderately worsened mental health.
Review maps how CB1 receptor activation drives hepatic insulin resistance and obesity, highlighting peripheral-only CB1 blockade as a promising therapeutic approach.
A systematic review of 85 studies found the majority linked cannabis smoking to increased risk of acute coronary syndrome and cardiovascular disease.
Review describes how cannabis can cause stroke through vasospasm, particularly in young people, alongside similar risks from other drugs of abuse.
Study of 1.2 million women found cannabis use disorder associated with 48% higher cardiovascular risk and doubled hemorrhagic stroke risk over up to 30 years.
An Australian study of 55 synthetic cannabinoid deaths found acute toxicity was the top cause but cardiovascular disease was strikingly common in these relatively young decedents, with AB-CHMINACA the most frequently detected compound.
Mouse inhalation study found vaporized cannabis (10.3% THC) decreased heart rate and blood pressure while promoting anxiety-like behavior and altering brain activation patterns.
Review identifies potential cannabis interactions with blood thinners: THC may increase warfarin levels (bleeding risk) and CBD may reduce clopidogrel activation (stroke risk) through liver enzyme inhibition.
Case series of 11 heavy marijuana users who developed small bowel intussusception requiring surgery, with no other identifiable cause in most cases.
Analysis of 7.3 million PCI patients found cannabis users had no worse in-hospital mortality, bleeding, or stroke, and had lower vascular complications compared to non-users.
A 21-year-old with no heart disease risk factors had four heart attacks over 18 months, each linked to cannabis use, and became symptom-free after quitting.
AHA first scientific statement on cannabis concluded cardiovascular harms (arrhythmia, MI, stroke) outweigh uncertain benefits, calling for Schedule 1 reclassification to enable research.
Review of 62 published cases found marijuana-linked heart attacks averaged age 27.7, with 37% having normal coronary arteries and 7 deaths.
Review found CB1 worsens and CB2 protects heart inflammation during ischemia, while cannabis use may trigger arrhythmias and metabolic dysfunction.
Electronic health record analysis found regular cannabis use was associated with higher rates of stroke, arrhythmia, and mortality, particularly in non-tobacco users.
A large genetic study found no causal relationship between cannabis use and type 2 diabetes risk. The analysis used genetic data from nearly one million people to separate causation from correlation.
Review found THC may increase heart attack risk through sympathetic activation and vascular dysfunction, while CBD shows preclinical cardioprotective effects, creating a complex risk profile.
Case of a 36-year-old with CHS who developed aortic blood clot and coronary disease requiring surgery because CHS vomiting prevented oral antiplatelet therapy.
A French nationwide study of 3.3+ million patients found cannabis was the only illicit drug independently associated with higher heart attack risk, though post-heart-attack outcomes were similar for drug users and non-users.
A nationwide VA study of 1.2+ million patients found cannabis use independently associated with 2.65 times the odds of premature cardiovascular disease, with greater risk in women and polysubstance users.
A 26-year-old chronic cannabis user developed heart block requiring a pacemaker. Electrophysiology testing revealed a novel pattern suggesting cannabis may directly damage cardiac conduction tissue.
A young cannabis user developed a rare, life-threatening blood clot in the left main coronary artery, raising questions about cannabis as a potential trigger for coronary thrombosis.
Among 33,343 US stress cardiomyopathy admissions, 210 marijuana-related cases were younger, had fewer traditional risk factors, but experienced more cardiac arrest, respiratory failure, and cardiogenic shock.
Review links cannabis use to increased cardiovascular risk, including nearly 5x higher MI risk, particularly affecting younger men immediately after consumption.
Review finds cannabis metabolic pathways overlap with transplant drugs, creating risks of unstable immunosuppression, graft failure, and infection in heart transplant recipients.
National analysis of 68 million hospital records finds cannabis use disorder associated with 28-52% higher odds of arrhythmia hospitalization in young adults, with atrial fibrillation most common.
A 63-year-old with inoperable coronary artery disease and unstable angina unresponsive to morphine experienced pain reduction and improved exercise capacity after starting edible medical cannabis.
A young recreational cannabis and tobacco smoker developed dilated cardiomyopathy leading to cardioembolic stroke and peripheral gangrene requiring amputation.
Study of 404 first-episode psychosis patients found cannabis users were less likely to develop metabolic syndrome, with lower triglycerides and higher HDL cholesterol.
Cardiac arrhythmias among teens hospitalized with cannabis use disorder increased sixfold from 2003 to 2016, with dramatically higher mortality (7.4% vs. 0.1%) and hospital costs when arrhythmia co-occurred.
CB1 receptor blockade with rimonabant reduced atherosclerotic lesions by 64% and improved lipid profiles in lean mice, showing cardiovascular benefits independent of weight loss.
First clinical description of fatal 4F-MDMB-BINACA intoxication: a 22-year-old died of multi-organ failure 11 days after extensively vaping this synthetic cannabinoid.
A 22-year-old with cannabinoid hyperemesis syndrome died after vomiting-induced hypokalemia triggered a fatal cardiac arrhythmia, complicated by QT-prolonging medications and cardiac genetic mutations.
Mendelian randomization found no broad causal link between cannabis use and cardiovascular disease, but after adjusting for tobacco and BMI, possible small effects on small vessel stroke (17% increase) and atrial fibrillation (6% increase) emerged.
Large Canadian cohort study found medical cannabis patients had 44% higher risk of ER visits or hospitalization for heart attack or stroke, with the association strongest in males (77% higher risk).
A 27-year-old with no traditional risk factors had a heart attack after cannabis use, showing significant coronary artery narrowing requiring stent placement.
A 24-year-old with no risk factors developed acute myocarditis with reduced heart function and a blood clot after marijuana use, representing a rare but serious cardiac complication.
First reported case of a 17-year-old developing superior mesenteric artery syndrome (bowel obstruction) from rapid weight loss caused by cannabinoid hyperemesis syndrome.
A study of 8,008 pregnant women found cannabis use altered placental blood vessel development markers and was associated with higher risk of pregnancy complications.
Children exposed to prenatal cannabis had higher BMI and body fat at age 10, but similar associations with paternal use suggest family lifestyle factors rather than direct fetal effects.
A genetic analysis found cannabis use disorder was independently linked to higher risk of atrial fibrillation, heart failure, pulmonary embolism, and stroke, beyond traditional cardiovascular risk factors.
Nationwide data showed young adults with cannabis use disorder had higher rates of hypertensive crisis and worse cardiovascular outcomes during hospitalization.
Among 3.3 million cannabis hospitalizations, pulmonary circulation disorders increased 200% over 7 years, with patients facing 2x the in-hospital mortality risk.
UK Biobank analysis found marijuana use associated with 15.6% lower heart attack incidence, comparable to the protective effect of moderate red wine consumption.
Double-blind RCT found nabiximols did not reduce spasticity after stroke compared to placebo, but demonstrated cardiovascular safety in this high-risk population, encouraging further research.
Review of 282 CHS emergency cases found anti-emetic medications did not significantly prolong QTc. Only low potassium (below 3.0) predicted dangerous QT prolongation.
Review found that cocaine, amphetamines, alcohol, and marijuana all contribute to premature cardiovascular disease in young and middle-aged adults, representing a growing public health problem.
Cardiology review found cannabis can trigger heart attacks, arrhythmias, Takotsubo cardiomyopathy, and arteritis in young healthy individuals. Complete abstinence is the recommended treatment.
Matched cohort in Hawaii found older cannabis users (50+) had higher rates of heart disease, stroke, chronic pain, MI, and used more healthcare services over two years compared to non-using controls.
Randomized crossover trial in 34 post-stroke patients found nabiximols caused no blood pressure changes, no heart rate changes, and no cardiovascular events during treatment.
First whole-genome sperm methylome study of cannabis exposure found 3,321 altered sites in rats, with changes detectable in offspring and associated with heart enlargement.
NHANES study of 7,159 adults found cannabis use associated with 60-87% higher odds of elevated cardiovascular disease risk scores in a dose-dependent pattern.
American Heart Association scientific statement concluded marijuana may adversely affect brain health through cognitive impairment and increased stroke risk, especially during neurodevelopment.
Review of 16 studies found marijuana use associated with increased risk of heart attack within 24 hours and stroke, especially in people with existing cardiovascular conditions.
Study of 3,424 adults found alcohol altered 2,569 DNA methylation sites and tobacco 528, but marijuana showed no significant changes, with alcohol-related methylation mediating hypertension risk.
Nationwide data showed heart attacks among young cannabis users nearly tripled from 2007 to 2018, with the steepest increase among Black Americans.
Largest-ever meta-analysis (183M patients) found cannabis use significantly associated with stroke risk but not heart attack risk — though observational data can't prove causation.
Case report of CHS presenting with ventricular bigeminy highlights potential cardiac complications of cannabinoid hyperemesis syndrome.
Canadian study of 60,000 adults found cannabis use disorder linked to 57% higher risk of cardiovascular events, with stronger relative risk in otherwise healthy individuals.
National database of 344,000 bypass patients found marijuana users had 40-64% higher odds of kidney injury, heart attack, and stroke after surgery despite being younger.
Mouse study found neither THC nor synthetic cannabinoid JWH-073 killed heart cells, but JWH-073 caused significantly greater blood vessel relaxation, offering a potential mechanism for cardiovascular events seen with K2/Spice products.
Rat muscle study found THC worsened alcohol-induced mitochondrial damage, with the most severe effects in young glycolytic muscles, suggesting combined cannabis-alcohol use may be particularly harmful to muscle energy production in younger individuals.
Isolated heart mitochondria from old rats showed nearly double the damage from THC compared to young rats, with alcohol worsening the effect and increasing harmful reactive oxygen species production.
National database analysis of 8.4 million young adult admissions found cannabis use disorder was associated with lower odds of pulmonary embolism hospitalization but longer stays and higher costs.
National database study of 39,992 patients found cannabis use disorder was not linked to cardiovascular events or arrhythmias but was significantly associated with higher in-hospital mortality.
A Danish nationwide study found prescribed medical cannabis for chronic pain was associated with doubled risk of new-onset arrhythmia within 180 days, though no link to heart attacks was found.
A survey of 140 transplant clinicians revealed significant disagreement on cannabis policies for heart transplant listing, with state legality strongly influencing program practices.
A survey of 434,104 US adults found daily cannabis use was associated with 25% higher heart attack risk and 42% higher stroke risk, with stronger effects in never-tobacco smokers.
A 7-year-old experienced cardiac arrest 7 hours after eating THC gummies, the first pediatric case of THC-induced asystole.
Two adolescent CHS cases and a literature review reveal dangerous QTc prolongation risks when haloperidol treatment compounds the cardiac effects of cannabis and electrolyte imbalances from vomiting.
Review of 59 studies finds prenatal cannabis exposure consistently predicts low birth weight followed by rapid weight gain, increased body fat, and higher glucose in childhood.
Systematic review finds smoking cannabis carries the most cardiovascular and respiratory risks, vaping may reduce respiratory harm, and edibles/dabbing are poorly studied.
Three cannabis extracts blocked LDL oxidation, foam cell formation, and inflammation through non-traditional receptors, targeting multiple steps of plaque development.
Propensity-matched analysis of 216K+ young men found cannabis use disorder was not significantly linked to atrial fibrillation after excluding tobacco users.
Adult rats exposed to a synthetic cannabinoid before birth showed sex-specific changes in breathing control, cardiovascular function, and anxiety behavior.
Low-dose JWH-018 for two weeks caused persistent cardiovascular effects, cardiac lesions, mitochondrial dysfunction, and multi-organ damage in rats that worsened after discontinuation.
Review of preclinical evidence suggests cannabinoids, especially CBD, could help manage pain, inflammation, and tissue damage after open-heart surgery.
CBD promoted heart cell regeneration and reduced heart attack damage in mice by downregulating miR-143-3p through the CB2 receptor, restimulating cardiomyocyte proliferation.
Review examines how cannabis affects the cardiovascular system, highlighting increased heart rate, blood pressure changes, and the problem of patients concealing their use from doctors.
Systematic review found cannabis smoking independently increases heart attack risk (aOR up to 5.24) after adjusting for tobacco, while non-smoked cannabis showed no significant cardiac risk.
Meta-analysis of seven studies finds cannabis use associated with 2.05x increased risk of ischemic stroke, with evidence particularly concerning for young adults.
NHANES analysis found lifetime cannabis use associated with 5.45x higher odds of coronary heart disease in adults 20-59 — a striking finding that demands cautious interpretation given the cross-sectional, self-reported design.
Prospective urine screening in 39 French cardiac ICUs found 21% of elderly patients tested positive for psychoactive substances, with cannabis at 18% of positives (3x lower than younger patients).
Smoking THC before exercise raised post-exercise pulse pressure and altered cardiac recovery, but blood pressure and heart performance during exercise were unaffected.
Meta-analysis of 81 million participants found cannabis use associated with 71% higher atrial arrhythmia risk, with concurrent drug use and legal country status further increasing risk.
A 45-year-old with 20 years of daily marijuana use required three vascular bypass surgeries for severe PAD despite having no diabetes, hypertension, or hyperlipidemia.
35-year CARDIA study of 4,328 adults found no association between cumulative cannabis use and developing hypertension, with results robust across sensitivity analyses.
Full-spectrum cannabis extract improved neurological function, protected gut barrier integrity, and reduced oxidative stress and lung inflammation in rats after induced stroke, showing broad protective effects beyond the brain.
A narrative review outlines four key cannabis safety concerns for healthcare professionals: mood effects, suicidal ideation associations, cardiovascular effects, and drug interactions, areas where clinical awareness lags behind expanding legal access.
Thiazide blood pressure medications have been unknowingly targeting the endocannabinoid system for over sixty years through the enzyme NAPE-PLD, generating protective anandamide signaling.
CBD treatment preserved heart function in mice with heart failure by maintaining mitochondrial function and calcium handling through PPARgamma receptors.
Review found cannabis users often need higher sedation doses for endoscopy, with inhalation users facing extra airway risks like bronchospasm.
Analysis of nearly 25,000 cannabis-related ER visits found 21.7% involved syncope (fainting), with an 8.6-fold higher prevalence compared to non-users.
A 63-year-old woman developed Takotsubo cardiomyopathy with an ejection fraction of 15-20% after cannabis use, requiring 4 weeks of intensive cardiac support to recover.
Placental tissue study found cannabis use completely eliminated endocannabinoid-mediated blood vessel relaxation and greatly reduced nitric oxide signaling.
A 26-year-old chronic cannabis user with no heart disease had a cardiac arrest with ventricular fibrillation and QTc prolongation, requiring prolonged rehabilitation for brain injury.
Young adults with cannabis use disorder showed significant drops in heart rate variability and increased heart rate immediately after smoking, measured by wearable smartwatches over 3 days.
Among 4,285 veterans with heart disease, cannabis smoking was linked to higher rates of heart attack, stroke, and cardiovascular death—though confounders remain.
A review finds prenatal cannabis exposure affects multiple organ systems beyond neurodevelopment, including cardiovascular, metabolic, and growth outcomes.
CBG relaxes human pulmonary arteries through endothelium-dependent mechanisms, modified by hypertension and high cholesterol.
CBD raised anandamide but this did not correlate with blood pressure reduction in 66 hypertensive patients.
Maternal omega-3 supplementation reversed THC-induced fetal growth restriction and cardiac deficits in rat offspring, possibly through reduced endocannabinoid signaling.
Among 772 heart attack patients across 39 French hospitals, 11% tested positive for cannabis and had over 3 times the odds of serious in-hospital complications like cardiac arrest or death.
A 13-year analysis of Canadian hospital data found cannabis-related hospitalizations rose 120% and ER visits rose 113%, driven largely by psychosis cases and youth intoxications.
Among 188 young heart attack patients (all smokers), the 41% who used cannabis had significantly worse cardiovascular outcomes over 3 years.
JAMA Cardiology study finds both cannabis smoking and THC edibles impair blood vessel function comparably to tobacco, though through apparently different mechanisms.
An Ontario study of 11.6 million people found that individuals hospitalized for cannabis use disorder were nearly 3 times more likely to die within 5 years, with especially high risks for suicide and trauma.
A study of 587,486 pregnancies found that while any cannabis use was not linked to hypertension, frequent use (2+ times weekly) was associated with 3.44 times higher odds of hypertensive disorders.
JWH-018, a synthetic cannabinoid, caused arrhythmias, ischemic damage, and heart attack-like tissue changes in rats, with effects worsening at higher doses and longer exposure.
Review finds cannabis has been linked to heart attacks since the 1970s, but current studies are too coarse to identify which users and use patterns carry the most risk.
Large database study found cannabis use associated with 30% lower mortality and less cirrhosis in liver disease patients, but 42% higher heart attack risk.
Mouse study showed combining alcohol with synthetic cannabinoids produced worse cardiac dysfunction than either alone, reversible by blocking CB1 receptors.
Study of 719 breast reconstruction patients found cannabis users had three times the hematoma risk and nearly three times the readmission rate.
Animal study found prenatal cannabinoid exposure impaired breathing reflexes and cardiovascular responses in juvenile rats, with sex-specific effects.
Comprehensive review finds cannabis use linked to heart rhythm disturbances, especially atrial fibrillation in young males, with synthetic cannabinoids posing even higher risk.
Case report of a 16-year-old with two years of unexplained recurrent vomiting finally diagnosed as cannabis hyperemesis syndrome, emphasizing the need for CHS awareness in pediatric care.
Meta-analysis of 17 studies (1.9 million people) found cannabis use associated with 48% higher risk of composite cardiovascular events, though individual associations with heart attack and stroke alone did not reach statistical significance.
Review of molecular, clinical, and forensic evidence shows cannabinoids can disturb cardiac electrophysiology and unmask hidden genetic heart rhythm disorders, potentially causing fatal arrhythmias.
Meta-analysis of 24 studies found cannabis use associated with 29% higher risk of acute coronary syndrome, 20% higher stroke risk, and 2.1-fold higher cardiovascular death risk.
A healthy 32-year-old had a heart attack requiring emergency stent placement after smoking synthetic cannabinoid Mojo.
A young man with no cardiac risk factors developed Wellens syndrome linked to cannabis smoking.
Cannabis smoke plus seed oil diet weakened heart function, suppressed anti-inflammatory mediators, and increased immune activation in mice.
CBD may protect the cardiovascular system through anti-inflammatory and vasoprotective effects, with early trials showing blood pressure reduction.
A study of 420,000+ matched patients found cannabis users had significantly higher rates of every type of arrhythmia studied, with the strongest association for dangerous ventricular arrhythmias (nearly 3× the risk).
National 2023 data showed various marijuana consumption methods were linked to increased coronary heart disease risk, with combined smoking and vaping showing the highest risk levels.
Mayo Clinic review of CBD's potential in cardiovascular medicine, covering anti-inflammatory and cardioprotective mechanisms across pericarditis, ischemic heart disease, and heart failure.
Vaping cannabis reduces some combustion harms but produces similar cardiovascular effects to smoking and introduces its own lung risks—not a safe alternative.
National database study found cannabis use disorder didn't worsen heart surgery outcomes after matching, but CUD patients had dramatically higher rates of polysubstance use.
Large Canadian study of 215,000+ people found medical cannabis patients had 15% higher risk of heart failure ER visits and hospitalizations compared to matched controls — a modest but clinically meaningful signal.
National survey of 88,000+ adults under 50 found daily cannabis use linked to 40% higher heart disease odds, with a clear dose-response: each additional 90 days of annual use increased risk by 9%.
One ED case: a “THC” gummy was analytically confirmed as HHC, with dissociative-like symptoms.
JAMA review found strong evidence for cannabinoids treating nausea, appetite loss, and seizures, but guidelines recommend against inhaled or high-potency cannabis for most conditions.
Comprehensive review finds that CB2 receptor activation and peripheral CB1 receptor blockade show the most promise for preventing harmful cardiac scarring through anti-inflammatory and antioxidant mechanisms.
Decade-long cohort study of 3,610 people finds cannabis use is not associated with ECG abnormalities regardless of HIV status, though sex and HIV independently affect cardiac findings.
Narrative review suggests cannabis may be an underrecognized risk factor for peripheral arterial disease through vasospasm, endothelial damage, and platelet changes, particularly affecting younger patients.
Phase 2 RCT: CBD missed primary cardiac endpoints but significantly reduced LV mass and showed anti-inflammatory trends in myocarditis.
Prospective French study finds recreational drug use, including cannabis, nearly tripled the risk of major cardiac events at one year post-hospitalization.
Survey of 549 sexual minority men found cannabis users had 83% higher odds of erectile dysfunction, highlighting an understudied intersection of cannabis and sexual health.
Review mapped how cannabinoids interfere with drug metabolism through CYP450 enzymes, potentially altering effectiveness of antidepressants, blood thinners, opioids, and more.
Analysis of 988 schizophrenia patients found THC-positive individuals had 36% lower odds of metabolic syndrome, with significantly less central obesity.
Matched study of ~250,000 patients per group found cocaine users had significantly more arrhythmias, heart attacks, strokes, and deaths than cannabis users.
Meta-analysis of 100+ million participants plus genetic analysis confirms cannabis use disorder is causally linked to stroke, particularly large artery stroke.
National study of 437,000 US adults found cannabis use associated with increased stroke risk (28% higher for non-daily users), with stronger associations for daily use.
A 32-year-old died from 4F-MDMB-BICA, a synthetic cannabinoid up to hundreds of times more potent than marijuana, with coronary disease as a contributing factor.
NHANES analysis of nearly 6,000 middle-aged adults found frequent cannabis use linked to significantly lower Klotho, an aging biomarker, with a dose-dependent relationship.
NHANES analysis of nearly 13,000 adults found current marijuana users showed accelerated biological aging, with cadmium from smoke explaining about 8-16% of the effect.
Cannabis elevates heart attack risk 4.8x in the first hour after use — similar to heavy exercise (5.9x) and anger (2.3x) — but the absolute risk is low.